Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis

M. Arboix, E. Rey, F. Clos, J. Camarasa

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Acenocoumarol is an oral anticoagulant of the coumarin group which has not been precisely characterized with respect to its kinetic behaviour after oral administration. This study was conducted in 10 patients with valvular prosthesis and on long-term acenocoumarol therapy. In those who were administered an oral dose of 0.11 ± 0.01 mg/kg, it was observed that acenocoumarol presents a slow and erratic absorption, reaching maximum concentration between one and three hours after administration. The plasma elimination half-life of approximately six hours is shorter than that of other coumarins widely used in the clinic, such as warfarin or phenprocoumon.
    Original languageEnglish
    Pages (from-to)33-36
    JournalRevista de Farmacologia Clinica y Experimental
    Volume2
    Issue number1
    Publication statusPublished - 1 Jan 1985

    Fingerprint Dive into the research topics of 'Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis'. Together they form a unique fingerprint.

    Cite this